Vigil Neuroscience Inc
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States. The company's lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells… Read more
Vigil Neuroscience Inc (VIGL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.496x
Based on the latest financial reports, Vigil Neuroscience Inc (VIGL) has a cash flow conversion efficiency ratio of -0.496x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.48 Million) by net assets ($41.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vigil Neuroscience Inc - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Vigil Neuroscience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Vigil Neuroscience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vigil Neuroscience Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Exmar NV
PINK:EXMRF
|
N/A |
|
Nanjing Toua Hardware&Tools Co.Ltd.
SHE:301125
|
0.032x |
|
Sodick Co., Ltd.
PINK:SDCKF
|
N/A |
|
CLOUDBERRY CL.EN. NK -25
F:52K
|
N/A |
|
Oxford Biomedica plc
PINK:OXBDF
|
-0.083x |
|
Probe Metals Inc
OTCQB:PROBF
|
-0.217x |
|
Fujian Raynen Tech Co Ltd
SHG:603933
|
0.038x |
|
Cabaletta Bio Inc
NASDAQ:CABA
|
-0.247x |
Annual Cash Flow Conversion Efficiency for Vigil Neuroscience Inc (2020–2024)
The table below shows the annual cash flow conversion efficiency of Vigil Neuroscience Inc from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $71.64 Million | $-51.22 Million | -0.715x | -18.14% |
| 2023-12-31 | $116.25 Million | $-70.36 Million | -0.605x | -75.66% |
| 2022-12-31 | $189.08 Million | $-65.15 Million | -0.345x | -160.81% |
| 2021-12-31 | $-69.44 Million | $-39.35 Million | 0.567x | +209.37% |
| 2020-12-31 | $-28.28 Million | $-5.18 Million | 0.183x | -- |